SCHEMBL23301615

SCHEMBL23301615

Cc1cccc(Cl)c1-c1cc(NC2CCN(C(=O)OC(C)(C)C)CC2)c2cc(N)ncc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.45
CNR2 P34972 1/20 0.45
ABL1 P00519 1/20 0.43
CCNT1 O60563 1/20 0.43
BTK Q06187 1/20 0.42
SYK P43405 1/20 0.42
STS P08842 1/20 0.41
CCNA2 P20248 2/20 0.41
CDK2 P24941 2/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
BRD4 O60885 1/20 0.41
EPHX2 P34913 2/20 0.41
CCNK O75909 1/20 0.41
CCND3 P30281 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29897344 1.00 CNR1 (0.45) CNR1CNR2ABL1CCNT1BTK
SCHEMBL25044291 0.92 CCNT1 (0.45) CNR1CNR2CCNT1SYKSTS
SCHEMBL29897350 0.92 ABL1 (0.43) CNR1CNR2ABL1CCNA2CDK2
SCHEMBL23301670 0.92 ABL1 (0.43) CNR1CNR2ABL1CCNA2CDK2
SCHEMBL23301537 0.91 BTK (0.44) CNR1CNR2ABL1CCNT1BTK
SCHEMBL29897394 0.91 BTK (0.44) CNR1CNR2ABL1CCNT1BTK
SCHEMBL23301070 0.88 ABL1 (0.45) ABL1SYKCDK2L3MBTL1JAK1
SCHEMBL23328348 0.88 DYRK1A (0.46) CNR1CNR2CCNT1BTKSYK
SCHEMBL25044007 0.87 CNR1 (0.47) CNR1CNR2ABL1CCNT1BTK
SCHEMBL25044178 0.86 PIK3CD (0.44) ABL1BTKSYKBRD4PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637428-B2 Isoquinoline derivatives as SIK2 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2026-05-26 US disclosed
US-20230045929-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-02-16 US disclosed
US-20230045929-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-02-16 US disclosed
WO-2021084264-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-06 WO disclosed
WO-2021084265-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637428-B2 Isoquinoline derivatives as SIK2 inhibitors SIK2, SIK1, SIK3 CNR1 265/4885CNR2 178/4885ABL1 407/4885
US-20230045929-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS SIK2, SIK3, SIK1 CNR1 2449/4885CNR2 1753/4885ABL1 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.